Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona’s Chief Scientific Officer, has been released by the Investing News Network. In this interview, Dr. Deliencourt-Godefroy unveils Sirona’s ambitious plans to introduce its innovative anti-aging product, GlycoProteMimTM, to the markets of North America and Europe in early 2025.
Related news for (SRBCF)
- Sirona Biochem Announces Debenture Financing
- Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH
- Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report
- GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report
- SIRONA BIOCHEM Corporate Update April 2024